gt-02287
·Code: GT-02287
gt-02287: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Gain Therapeutics, Inc. (GANX) | Phase 2 |
Clinical Trials (1)
An Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Participants With Parkinson's Disease With or Without a Pathogenic GBA1 Mutation
Frequently asked questions
Who is developing gt-02287?
gt-02287 is being developed by Gain Therapeutics, Inc..
How many clinical trials involve gt-02287?
BioSniper tracks 1 clinical trial involving gt-02287.
Get deeper analysis on gt-02287
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis